Rim Semiconductor Company files Patent: related news

Rim Semiconductor Files Patent Application

July 10, 2008 (FinancialWire) Rim Semiconductor Co. (OTCBB: RSMI) (Current Market Cap. US$356,698.00) filed a non-provisional patent application on its RQAM technology. Rim Semi s Cupria transport processor is based on this RQAM technology, and is able to drive data traffic at more than 40 megabits per second. Existing technologies are able to drive data 15 mbps at this distance on this wire type. The patent, titled Amplitude Modulation Decoder, was filed as a non-provisional patent with the United States Patent and Trademark Office. It was also filed under the Patent Cooperation Treaty. This protects Rim Semi s intellectual property rights across a wide geography. Other companies trading in Rim Semi s industry include ABB Ltd. (NYSE: ABB), Eaton Corp.

Rim Semiconductor Company Files Patent for Breakthrough Technology

PORTLAND, Ore. - Rim Semiconductor Company (OTCBB: RSMI), a company that develops technology for telecommunications service providers, filed a non-provisional patent application on its innovative RQAM™ technology. Rim Semi’s Cup

Rim Semiconductor Company Files Patent for Breakthrough Technology

PORTLAND, Ore.--(BUSINESS WIRE)--Rim Semiconductor Company (OTCBB: RSMI), a company that develops technology for telecommunications service providers, filed a non-provisional patent application on its innovative RQAM

Rim Semiconductor Company Files Patent for Breakthrough Technology

PORTLAND, Ore.--(BUSINESS WIRE)--Rim Semiconductor Company (OTCBB: RSMI - News), a company that develops technology for telecommunications service providers, filed a non-provisional patent application on its innovative RQAM

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

Rim Semiconductor Company files Patent

Rim Semiconductor Company’s technology, allows data traffic to be processed at 40 megabits per second (Mpbs) 5,500 feet (1.67km) on 26AWG (0.40mm) telephone wire, all thanks to its new Cupria™ transport processor, which is actually based on the soon to be patented RQAM technology.

InvestSource Inc.: Rim Semiconductor Company Files Applies For Patent

Stocks in the News: Rim Semiconductor Company (OTCBB: RSMI), KLA-Tencor (NASDAQ: KLAC), Teradyne, Inc. (NYSE: TER), Applied Materials, Inc. (NASDAQ: AMAT)

InvestSource Inc.: Rim Semiconductor Company Files Applies For Patent

Jul 11, 2008 (M2 PRESSWIRE via COMTEX) -- TER | Quote | Chart | News | PowerRating -- Stocks in the News: Rim Semiconductor Company (OTCBB: RSMI), KLA-Tencor (NASDAQ: KLAC), Teradyne, Inc. (NYSE: TER), Applied Materials, Inc. (NASDAQ: AMAT)

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

EV Group Files Patent Infringement Lawsuit Against the 3M Company

EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

EV Group Files Patent Infringement Lawsuit Against the 3M Company

ST. FLORIAN, Austria, July 14 /PRNewswire/ -- EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

EV Group Files Patent Infringement Lawsuit Against the 3M Company

ST. FLORIAN, Austria, July 14 /PRNewswire/ -- EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

EV Group Files Patent Infringement Lawsuit Against the 3M Company

ST. FLORIAN, Austria, July 14 /PRNewswire/ -- EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

JPEG Patent's Single Claim Rejected (And Smacked Down For Good Measure)

We've been covering the ongoing saga of an old patent we've referred to as the "JPEG Patent." This actually isn't the first patent we've called the JPEG Patent, because multiple people claimed to hold patents over the technology that goes into a JPEG image. But, this one was rather special. The patent had been used, repeatedly, by lawyer Ray Niro, against a wide range of opponents, including a patent system critic. The end result was a drawn out review process where all of the original claims were rejected, but a single new claim was added to the patent, which Niro insisted covered JPEGs on a website.

MIT sues Affymetrix for patent infringement

Affymetrix, the Santa Clara maker of tools used to study DNA and diagnose diseases, was sued for patent infringement by the Massachusetts Institute of Technology over the company's GeneChip system used to analyze genes. Affymetrix has knowingly infringed the patent, MIT and a company started by an MIT professor said in a federal court complaint filed Tuesday in Boston. Affymetrix filed an application with the U.S. Patent and Trademark Office in September 2004, six months after a similar patent was approved for MIT, the university said in its complaint. The patent regulators ruled in May 2007 that the MIT group was the first inventor, according to the complaint. The GeneChip technology is used to develop new therapeutic drugs and to investigate the cause of cancer, AIDS and other diseases, Affymetrix has said.

Alnylam Loses Challenge In Europe On Key Patent Covering Gene-Silencing Technology

July 14, 2008 (FinancialWire) Shares of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) fell after the company said that it lost a challenge in Europe on a key patent which covered certain areas of its gene-silencing technology. Alnylam said claims on the "Glover" patent were overturned by the Opposition Division of the European Patent Office. The patent is licensed from Cancer Research Technology Ltd. and Alnylam said it plans to appeal the decision. Alnylam said that the decision does not alter the position of the company's intellectual property for developing and commercializing RNAi therapeutics, nor does it impact any ongoing business development discussions. The patent is one of 11 held by Alnylam. The goal of gene-silencing, or RNA-based, treatments is to turn off, or silence- the gene at the root of a medical condition, treating the a

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

MIT Files Patent Suit Against Biotech Company Affymetrix

MIT filed a lawsuit against biotechnology company Affymetrix last month, alleging the company’s GeneChip technology infringes an existing MIT patent.

PATENT REFORM IS NOT NECESSARY

Virtually all of the problems of the U.S. Patent system, including the high cost of obtaining a patent can be attributed to examiners issuing improper "bogus" rejections. While I know this is tue from my experience as a patent examiner, I performed a survey {using the PTO's Patent Application Information Retrieval (PAIR) system} of the 50 most recently issued patents classified in Class 435, Chemistry: Molecular Biology and Microbiology. In 76% of these patents, the examiner indicated in the first Office action that there was no allowable subject matter, i.e. none of the claims are patentable. Are the abilities of patent attorneys so low that over 75% of patent applications as filed do not contain at least one allowable claim? Or are the examiners writing "bogus" rejections? The answer is the latter.

Danish biopharmaceutical company Bavarian Nordic A/S files patent infringement suit against Oxford BioMedica Plc

Danish biopharmaceutical company Bavarian Nordic A/S files patent infringement suit against Oxford BioMedica Plc

Search took 0.80 seconds.